Speech therapy
ProcedurePatients will connect on an interface to pratice speech therapy
NCT Number: NCT05609084
Out of 30,000 new cases per year in France, 30% of epileptic patients are drug-resistant. Neurosurgery, which consists in resecting the epileptogenic zone, is the only chance of cure. In the case of temporal epilepsy of the language-dominant hemisphere (TLE), this procedure presents a high risk of increasing cognitive difficulties and may even be contraindicated for this reason alone. The difficulties found are impairments in lexical access (anomia) and verbal memory and affect more than 60% of patients . Preoperative cognitive rehabilitation could influence brain plasticity mechanisms but there are currently no recommendations on this topic. In this context, the investigators have developed a speech rehabilitation procedure specific to the needs of ELTPR patients. They rely on cognitive hypotheses explaining the disorders but also on models of rehabilitation-induced neural plasticity likely to improve cognitive reserve before surgery. The investigators hypothesize that preoperative cognitive language rehabilitation in ELTPR patients may decrease surgical risk and improve postoperative language prognosis.
The primary objective is to demonstrate the protective efficacy of preoperative speech rehabilitation on language performance postoperatively.
Interested in participating?
Request Info16 year and older
All sexes
Interventional
Not applicable
Service EFSN - Hôpital Pellegrin, Bordeaux, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will connect on an interface to pratice speech therapy
Patients will be followed by an speech therapist
Time frame: Day 7 after surgery
Number of images quoted
Time frame: 6 months after surgery
Number of images quoted
Time frame: Day 7 after surgery
% of correct answers of language tests
Time frame: 6 months after surgery
% of correct answers of language tests
Time frame: Day 7 after surgery
Verbal memory task
Time frame: 6 months after surgery
Verbal memory task
Time frame: Day 7 after surgery
Lexical evocation tests limited to 2 minutes according to a formal criterion or an imposed categorical criterion
Time frame: 6 months after surgery
lexical evocation tests limited to 2 minutes according to a formal criterion or an imposed categorical criterion
Time frame: Day 7 after surgery
Number of words quoted
Time frame: 6 months after surgery
Number of words quoted
Time frame: Day 7 after surgery
Use of an ad-hoc scale graduated from 0 (no complaint) to 10 (maximum complaint)
Time frame: 6 months after surgery
Ad-hoc scale graduated from 0 (no complaint) to 10 (maximum complaint)
Time frame: Day 7 after surgery
Quality Of Life in Epilepsy Inventory (QOLIE-31) (0 meaning better outcome, highest score meaning worse outcome)
Time frame: 6 months after surgery
Quality Of Life in Epilepsy Inventory (QOLIE-31) (0 meaning better outcome, highest score meaning worse outcome)
Time frame: 6 months after surgery
Number of speech therapy sessions performed postoperatively
Contact information is provided by the study sponsor or research team.
Assistance Publique Hopitaux De Marseille
Other
Acronym: REPREO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07202494
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Marseille, France
View Trial DetailsNCT01273129
Brain Diseases, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03478852
Brain Diseases, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06492720
Brain Diseases, Central Nervous System Diseases
Taipei, Taiwan
View Trial Details